

UBAM – GLOBAL RESPONSIBLE CONVERTIBLE BOND

Quarterly Comment

For Professional Investors in Switzerland or Professional Investors as defined by the relevant laws. The classification of the fund(s) as per the Sustainable Finance Disclosure Regulation (SFDR) is available on ubp.com or in the latest prospectus.

Market Comment

- After the spike in volatility during March, the quarter started on a much quieter stance as equities rebounded and credit spreads and rates stabilized over April. With the US President Joe Biden and Kevin McCarthy, Speaker of the United States House of Representatives, eventually reaching an agreement to raise the nation's borrowing limit a new episode of volatility over the US debt ceiling has been avoided. Most of the quarterly equity market performance has actually been delivered in June, driven by technology and consumer names, in the electrical vehicle and travel themes in particular. Markets found support in the resilient US economy and slightly more hawkish tone from the US Federal Reserve. The Fed rose its interest rate to 5.25% over the quarter, with only one rate hike of 25bps in May. In the meantime, the ECB increased its policy rates by 50bps and the BOE hiked twice for a total of 75bps. Their main focus is still inflation which hasn't fallen enough. US 10-year rate has risen by 36bps to 3.48% over the quarter. Overall volatility has fallen through Q2 across asset classes. High Yield credit spreads tighten during Q2 down by 53bps and 28bps in the US and Europe respectively.
- Major equity markets delivered positive performances over the second quarter of the year and global equities ended the quarter up 7.0% (MSCI World TR). In the US, the S&P 500 index increased by 8.7% quarter-on-quarter; cross-Atlantic, the Stoxx Europe 600 index lagged being up only 2.7% q/q and the Nikkei 225 index outperformed, up 18.5% q/q (all performance expressed in local currencies). In terms of investment styles, there was an outperformance of the Growth segment over the Value (10.6% q/q for the S&P Growth index, 4.0% ahead of the S&P Value index). US Quality small cap lagged with the Russell 2000 Quality moving only 4.2% higher.
- Being up 3.0%, convertible bonds exhibited an encouraging behavior showing its capacity to both rally when market environment improves and to mitigate downside risk.
- Primary market confirmed its rebound with the introduction of close to \$20 billion of convertible bonds during the second quarter of 2023. The US contributing \$14.3bn, Europe \$2.0bn and Asia \$2.5bn and Japan \$0.8bn. H1 2023 issuance has reached \$40bn. This is 4 times the level seen in H1 2022 and in line with pre-covid trend (\$76bn issued annually between 2010 and 2019).

Performance Review

- Over Q2, UBAM – Global Responsible Convertible Bonds (IC EUR share class) posted a net return of 1.9% bringing the year-to-date performance to 2.5%. This is behind its Global convertible bonds universe (represented by the Refinitiv Global Convertible Bond index hedged in Euro, “the index”) which returned 3.0% q/q and 7.0% since the beginning of the year. Most of the quarterly underperformance materialised in June and is coming from the US region. Underperformance was driven by companies displaying weak financial fundamentals, more specifically heavy balance sheets, and weak ESG profiles such as cruise liners. We tend to be structurally underexposed to this type of companies as we focus on strong credit quality. In terms of sectors, we've seen strong upward movement on the back of the enthusiasm over generative AI which boosted technology names. It has had some positive knock-on effect on the semi-conductor sector. At issuer level, top absolute contributors in Q2 include MongoDB (US Software & Services), Palo Alto (US Software & Services), and Conmed (US Healthcare). Main detractors were Jazz Pharmaceuticals (US Healthcare), Solaredge (US Technology) and STMicroelectronics (Europe Semiconductor).

Portfolio Activity

- At the end of June, the average equity sensitivity of UBAM – Global Responsible Convertible Bond stands at 41.7% (+5.6pts q/q), -3.4pts below its index. The strategy's interest rate sensitivity remains low, at 1.4 for a 3.0-year duration. The average credit spread of the portfolio closed at 212bps versus 367bps for the index, reflecting the quality bias inherent to our philosophy.
- From a geographical standpoint, the fund is primarily exposed to equity markets through investments in the US (22.6%). Investments in Europe account for 17.5% and Asia and Japan for 1.7%. Relative to the index, the portfolio exhibits an overweight stance to Europe (+10.4pts equity sensitivity) while it is slightly less exposed to the US (-3.9pts) and Asian (-2.9) markets.
- Supported by a busy primary market we initiated several new positions that are in line with our Quality positioning. On the European market we initiated a position in Veolia 2025, a French company providing solutions to optimize resources management services such as water, waste, and energy management solutions. Through its three complementary activities, the group helps to develop access to resources, preserve available resources, and to replenish them. We invested in the 2027 convertible from MTU Aero, the profile being more convex. In the US we participated in the new issue from Dexcom, which has a maturity in 2028. Therefore, we are now invested in the company via two convertibles, maturity 2025 and 2028. The new issue from Lumentum, with a maturity in 2029, was an opportunity to operate a switch from the Lumentum 2028 into a more balanced profile. Over the quarter, we have made some arbitrage in our positions to rebuild exposure to more convex convertible bonds. It was the case for Halozyme and STMicroelectronics where we switched for convertibles with longer maturity. We closed our position in Silicon Labs in April, as the company announced they will redeem the convertible by end of June 2023. After the strong performance of the BE semiconductor stock (+27% in May), we took some profit and reduced slightly our exposure on the convertible BE semiconductor 2029. We also started to take profits on LVMH as after good performances the convertible bond has now a more equity-like profile.

Outlook

- Over the first months of the year central banks have continued to tighten their monetary policy, the upper bound of the Fed fund rates is now at 5.25% and the ECB's deposit rate is at 3.5%. The strong labor market and lower inflation legitimate their actions. That being said, the macroeconomic environment has shown signs of a desynchronized cycle both regionally and in sector terms. Economic surprise index in Europe has been falling sharply while the US one has shown more resilience. In this context, uncertainty around the future decisions from central banks persists and the uneven market performances create confusion. Indeed, we noticed that for the S&P 500, 5 out of 11 sectors, under the GICS classification, are still in negative territory year-to-date while 3 sectors have performances above 30%.
- Equity and bond markets are sending mixed messages and rather opposite views of the current state of the cycle. In one hand market implied rates are anticipating the first cut from the Fed as soon as Q1 2024, which is in line with significant slowdown in economic growth. In the other hand, equities are rising, and consensus expectations are showing a rebound in earnings growth by Q1 2024, this would be supported by stronger economic activity.
- We stay cautious as the strong momentum in equity markets is not a proper reflection of the current economic environment. With growth slowing down, mixed economic indicators and tighter credit conditions we believe it is paramount to invest in companies with strong fundamentals.
- Convertible bonds underlying equities are not expensive anymore and yield is back in the convertible bond universe. As a result, the outlook for convertible bonds is positive thanks to restored multiple performance drivers: underlying equity upside potential, yields and credit.
- Convertible bonds offer portfolio diversification and allow investor to maintain an exposure to the equity market while containing its downside risk. Over the medium-term convertible bonds have the potential to deliver better risk-adjusted returns.



SRI Comment & Indicators

■ **Holding comment: Focus on Dexcom, Medical Equipment & Devices**

- Dexcom solutions are centered around positively impacting the lives of people with diabetes. The number of adults living with diabetes has reached an estimated 537m which is equivalent to >9%+ of the world's adult population, and which is 4x higher than the number of cases recorded four decades previously. Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver. With the 2018 approval of the Dexcom G6 CGM system, the group eliminated the need for customers to fingerstick to calibrate their CGM. The latest version of its CGM, the G7 has been launched in Europe in 1H22 and in 1Q23 in the US. The G7 device is 60% smaller than the G6 and is composed of a simple auto-applicator, a slim sensor (measures glucose just beneath the skin) a transmitter, and an app. Device can be carried up to 15 days.
- Dexcom has identified access to its systems as a core element of its sustainable growth. The group is participating actively within the diabetes community providing direct support of non-profit organizations and clinical research.
- To manage its environmental externalities, Dexcom has implemented a sustainability software framework to track its industrial facilities' ecological footprint and GHG emissions. It now discloses its carbon inventory: Scope 1 emissions (company facilities – gas), Scope 2 emissions (purchased electricity, steam, heating, and cooling for own use), and select Scope 3 emissions (waste generated in operations) for its company. Several efficiency projects have also been initiated at manufacturing sites, with a goal to reduce energy usage such as the installation of solar panels and new transportation management solution system to eliminate unnecessary shipping.
- As medical equipment companies, Dexcom's major social issues are tied to product safety, affordability, and ethical marketing. Dexcom has internal quality management system in compliance with applicable US and international regulatory requirements. This includes compliance with key standards such as the FDA Quality System Regulation (QSR) and International Organization for Standardization (ISO) 13485. In 2022 its QRS has been certified under the Medical Device Single Audit Program across all applicable facilities. Access initiatives include a dedicated organisation that regularly engages with government and private players to pursue reimbursed access. The group had no monetary losses in 2022 as a result of legal proceedings associated with false marketing claims.
- Looking at governance, Dexcom's Board of directors has an independent majority with 11 directors out of which 10 independent members, and three women. The CEO, Kevin Sayer, acts also as the Chairman of the Board since July 2018 which may raises some leadership concerns. Prior to his role as Chairman and CEO, Kevin has served as a member of Dexcom's Board of Directors beginning in November 2007. He is backed by fully independent audit, compensation, and nomination committees. Pay practices doesn't yet incorporate sustainability performance criteria into the incentive scheme.

Sources: UBP, MSCI ESG Research.

Extra-financial performance indicators (June 30, 2023)¹

	Fund	Index²
Weighted average Carbon Intensity (tons CO2e / \$M Sales)	80	298
Exposure to fossil fuel reserves (%)	0.0	4.5
Diversity program (%)	76.6	54.5
Female directors (%)	35.5	30.7
Board independency (%)	81.2	74.3
Global Compact norm violation exposure (%)	0.0	0.2
Labor norm violation exposure (%)	0.0	0.0

¹Source: @ 2022 MSCI ESG Research LLC (see important disclaimer on page 4). ²Refinitiv Global Hedged Convertible Bond Index (EUR).

¹Source: @2022 MSCI ESG Research LLC – Reproduced by permission; data as at 30.06.2022. Although UBP SA's information provider – including, without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties") – obtain information from sources they consider reliable, none of the ESG parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Disclaimers

This is a marketing document and is intended for informational and/or marketing purposes only. It is intended to be used only by the person(s) to whom it was delivered. It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group (UBP). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Professional clients in Switzerland or Professional clients or an equivalent category of investor as defined by the relevant laws (all such persons together being referred to as "Relevant Persons").

This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. **Past performance is not a guide to current or future results.** The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not constitute forecasts or budgets; they are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. The contents of this document should not be construed as any form of advice or recommendation to purchase or sell any security or funds. It does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of a fund or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make their own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional counsel from their financial, legal and tax advisors. The tax treatment of any investment in a Fund depends on the investor's individual circumstances and may be subject to change in the future. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this presentation may be recorded. UBP will assume that, by calling this number, you consent to this recording.

Pursuant to Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector (the "Disclosures Regulation" or "SFDR"), funds are required to make certain disclosures. Funds falling under the scope of Article 6 of the SFDR are those which have been deemed not to pursue an investment approach that explicitly promotes environmental or social characteristics or has sustainable investment as their objective. The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities. Notwithstanding this classification, the Investment Managers may take account of certain sustainability risks as further described in the fund's prospectus. Funds falling under the scope of Articles 8 or 9 of the SFDR are those subject to sustainability risks within the meaning of the SFDR. The sustainability risks and principal adverse impacts as stipulated in the SFDR are described in the prospectus. In addition, unless otherwise specified, all funds apply the UBP Responsible Investment policy, which is available on <https://www.ubp.com/en/investment-expertise/responsible-investment>

UBP relies on information and data collected from ESG third party data providers which may prove to be incorrect or incomplete. Although UBP applies a proven selection process of such third-party providers, its processes and proprietary ESG methodology may not necessarily capture appropriately the ESG risks. Indeed, data related to sustainability risks or PAI are today either not available or not yet systematically and fully disclosed by issuers, may be incomplete and may follow various methodologies. Most of the ESG factors information is based on historical data that they may not reflect the future ESG performance or risks of the investments.

ESG information providers: Although Union Bancaire Privée, UBP SA, ESG information providers (the "ESG Parties") obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Any subscriptions not based on the funds' latest prospectuses, KIDs or KIIDs (as appropriate), annual or semi-annual reports or other relevant legal documents (the "Funds' Legal Documents") shall not be acceptable. The KID is also available in the local language of each country where the share class is registered and available on UBP Website: <https://www.ubp.com/en/funds.html>. The Funds' Legal Documents may be obtained free of charge from Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland (UBP), from UBP Asset Management (Europe) S.A., 287-289 route d'Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg, and from Union Bancaire Gestion Institutionnelle (France) SAS, 116 avenue des Champs-Élysées, 75008 Paris, France. The English version of the prospectus of the Fund as well as a summary of investor rights associated with an investment in the Fund are available on www.ubp.com. The fund's management company may decide to terminate or cause to terminate the arrangements made for the marketing of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC. The Swiss representative and paying agent of the foreign funds mentioned herein is UBP. The Funds' Legal Documents may be obtained free of charge from UBP, as indicated above.

This content is being made available in the following countries:

Switzerland: UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). The head office is Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland. ubp@ubp.com | www.ubp.com

United Kingdom: UBP is authorised in the United Kingdom by the Prudential Regulation Authority (PRA) and is subject to regulation by the Financial Conduct Authority (FCA) and limited regulation by the PRA.

Union Bancaire Privée, UBP SA | Asset Management
Rue du Rhône 96-98 | P.O. Box 1320 | 1211 Geneva 1 | Switzerland | www.ubp.com

France: Sales and distribution are carried out by Union Bancaire Gestion Institutionnelle (France) SAS, a management company licensed by the French Autorité des Marchés Financiers, - licence n° AMF GP98041; 116, av. des Champs Elysées I 75008 Paris, France T +33 1 75 77 80 80 Fax +33 1 44 50 16 19 www.ubpamfrance.com

Luxembourg: through UBP Asset Management (Europe) S.A., a Management Company authorised under Chapter 15 of the Law of 17 December 2010 relating to undertakings for collective investment (the "2010 Law") and an Alternative Investment Fund Manager authorised under the Law of 12 July 2013 (the "AIFM Law"), which manages undertakings for collective investment subject to Part I of the 2010 law and other types of funds which qualify as alternative investment funds. 287-289, route d'Arlon P.O. Box 79 1150 Luxembourg T +352 228 007-1 F +352 228 007 221.

Hong Kong: UBP Asset Management Asia Limited (CE No.: AOB278) is licensed with the Securities and Futures Commission to carry on Type 1 – Dealing in Securities, Type 4 – Advising on Securities and Type 9 – Asset Management regulated activities. The document is intended only for Institutional or Corporate Professional Investor and not for public distribution. The contents of this document have not been reviewed by the Securities and Futures Commission in Hong Kong. Investment involves risks. Past performance is not indicative of future performance. Investors should refer to the fund prospectus for further details, including the product features and risk factors. The document is intended only for **Institutional Professional Investor** and not for public distribution. The contents of this document and any attachments/links contained in this document are for general information only and are not advice. The information does not take into account your specific investment objectives, financial situation and investment needs and is not designed as a substitute for professional advice. You should seek independent professional advice regarding the suitability of an investment product, taking into account your specific investment objectives, financial situation and investment needs before making an investment.

The contents of this document and any attachments/links contained in this document have been prepared in good faith. UBP Asset Management Asia Limited (UBP AM Asia) and all of its affiliates accept no liability for any errors or omissions. Please note that the information may also have become outdated since its publication. UBP AM Asia makes no representation that such information is accurate, reliable or complete. In particular, any information sourced from third parties is not necessarily endorsed by **UBP AM Asia**, and **UBP AM Asia** has not checked the accuracy or completeness of such third-party information.

Singapore: This document is intended only for accredited investors and institutional investors as defined under the Securities and Futures Act (Cap. 289 of Singapore) ("SFA"). Persons other than accredited investors or institutional investors (as defined in the SFA) are not the intended recipients of this document and must not act upon or rely upon any of the information in this document. The financial products or services to which this material relates will only be made available to clients who are accredited investors or institutional investors under the SFA. This document has not been registered as a prospectus with the MAS. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this product may not be circulated or distributed, nor may the product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to institutional investors under Section 274 or 304 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to relevant persons pursuant to Section 275(1) or 305(1), or any person pursuant to Section 275(1A) or 305(2) of the SFA, and in accordance with the conditions specified in Section 275 or 305 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This advertisement has not been reviewed by the Monetary Authority of Singapore.